Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3721 in Moderate to Severe COPD
NCT07252908Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQC3721 in chronic obstructive pulmonary disease (COPD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2025; status: completed.
02
Drugs
TQC3721
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07252908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252908.